Tetra's promising drug for Alzheimer's disease is being developed in partnership with the NIH Blueprint Therapeutics program.
Our Scientific Advisory Board offers talent, experience, and a vision for new medicines.
The drugs in our pipeline offer a new mechanism focused on PDE4B and PDE4D.
Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information.
Working with potentially breakthrough technology, our goal is to improve the quality of life in patients suffering from